Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · BCLI · as of Jun 8, 2026
Activity summary
Buy transactions
13
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
13.00
Buy/Sell (by trades)
Overall sentiment
Brainstorm Cell Therapeutics Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
BCLI insider buying and selling by quarter
BCLI insider selling · BCLI insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · BCLI ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
BCLI executive sell shares · BCLI board member insider trading · BCLI insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 26, 2026 | Lebovits Chaim President & CEO | Award | 1,800,000 | — | Form 4 |
| Feb 26, 2026 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 150,000 | — | Form 4 |
| Feb 26, 2026 | Patlis Alla See Remarks | Award | 100,000 | — | Form 4 |
| Feb 26, 2026 | FRENKEL JACOB A Director | Award | 200,000 | — | Form 4 |
| Feb 26, 2026 | ARBEL IRIT Director | Award | 120,000 | — | Form 4 |
| Jan 1, 2025 | Dagher Ibrahim B. Chief Medical Officer | Award | 50,000 | — | Form 4 |
| Jan 1, 2025 | Lebovits Chaim President & CEO | Award | 120,000 | — | Form 4 |
| Jan 1, 2025 | FRENKEL JACOB A Director | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Polverino Anthony J. Director | Award | 24,000 | — | Form 4 |
| Jan 1, 2025 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 20,000 | — | Form 4 |
| Jan 1, 2025 | Yablonka Uri EVP & Chief Business Officer · Director | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Patlis Alla See Remarks | Award | 40,000 | — | Form 4 |
| Jan 1, 2025 | Naor Nir Director | Award | 30,666 | — | Form 4 |
| Jan 1, 2025 | Lindborg Stacy Director | Award | 20,000 | — | Form 4 |
| Jan 1, 2025 | HARTOUNIAN HARTOUN EVP, Chief Operating Officer | Award | 50,000 | — | Form 4 |
| Jan 1, 2025 | Bairu Menghisteab Director | Award | 24,000 | — | Form 4 |
| Jan 1, 2025 | ARBEL IRIT Director | Award | 30,666 | — | Form 4 |
| Sep 30, 2024 | Lebovits Chaim President & CEO | Purchase | 22,000 | $5K | Form 4 |
| Oct 1, 2024 | Lebovits Chaim President & CEO | Purchase | 1,836 | $6K | Form 4 |
| Jul 19, 2024 | Dagher Ibrahim B. Chief Medical Officer | Sale | 63,000 | $22K | Form 4 |
| Jun 24, 2024 | HARTOUNIAN HARTOUN EVP, Chief Operating Officer | Award | 30,000 | — | Form 4 |
| May 28, 2024 | Lebovits Chaim President & CEO | Award | 15,000 | $8K | Form 4 |
| May 22, 2024 | Lebovits Chaim President & CEO | Award | 25,000 | $16K | Form 4 |
| May 21, 2024 | Lebovits Chaim President & CEO | Award | 25,000 | $14K | Form 4 |
| May 13, 2024 | Lebovits Chaim President & CEO | Award | 10,000 | $5K | Form 4 |
Yablonka Uri
EVP & Chief Business Officer · Director
Date
Feb 26
Shares
150,000
Price
—
Value
—
Yablonka Uri
EVP & Chief Business Officer · Director
Date
Jan 1
Shares
20,000
Price
—
Value
—
Yablonka Uri
EVP & Chief Business Officer · Director
Date
Jan 1
Shares
40,000
Price
—
Value
—
HARTOUNIAN HARTOUN
EVP, Chief Operating Officer
Date
Jan 1
Shares
50,000
Price
—
Value
—
Dagher Ibrahim B.
Chief Medical Officer
Date
Jul 19
Shares
63,000
Price
$0.35
Value
$22K
HARTOUNIAN HARTOUN
EVP, Chief Operating Officer
Date
Jun 24
Shares
30,000
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About BCLI insider trading
BCLI insider trades
Brainstorm Cell Therapeutics Inc. (BCLI) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Lebovits Chaim (President & CEO), Yablonka Uri (EVP & Chief Business Officer · Director), Patlis Alla (See Remarks). Over the past 12 months, 5 insiders have filed transactions with the SEC. BCLI insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Brainstorm Cell Therapeutics Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
BCLI insider trading · 5 questionsThe insiders of Brainstorm Cell Therapeutics Inc. (BCLI) include executives and directors such as Lebovits Chaim (President & CEO), Yablonka Uri (EVP & Chief Business Officer · Director), Patlis Alla (See Remarks), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026